The FDA has approved a new option for the treatment of HIV-1 in adults as a replacement for current antiretroviral regimens in patients who are virologically suppressed and with no history of treatment...
The FDA has approved a treatment option for adults with multidrug resistant HIV infection, marking a “new class of antiretroviral medications” for this patient population.
The US Food and Drug Administration approved a drug for the treatment of HIV-1 infection in conjunction with other antiretroviral therapies among children aged at least 4 weeks who weigh at least 3 kg. ...
After performance data showed 95% sensitivity and specificity, the FDA authorized the assay’s marketing in the United States for detection of HIV-1 drug-resistant mutations.
After 2 randomized clinical trials found it as safe and effective as the standard 3-drug regimen, the FDA approved the first 2-drug regimen for adults with HIV-1 who have never been treated with ART.